DVAX PE Ratio & Valuation,Is DVAX Overvalued

DVAX Relative Valuation

DVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DVAX is overvalued; if below, it's undervalued.

Historical Valuation

Dynavax Technologies Corp (DVAX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.30 is considered Undervalued compared with the five-year average of -3.85. The fair price of Dynavax Technologies Corp (DVAX) is between 294.64 to 303.53 according to relative valuation methord. Compared to the current price of 10.80 USD , Dynavax Technologies Corp is Undervalued By 96.33%.

Relative Value

Fair Zone

294.64-303.53

Current Price：10.80

96.33%

Undervalued

18.79

23.30

EV/EBITDA

Dynavax Technologies Corp. (DVAX) has a current EV/EBITDA of 23.30. The 5-year average EV/EBITDA is 64.40. The thresholds are as follows: Strongly Undervalued below -330.16, Undervalued between -330.16 and -132.88, Fairly Valued between 261.68 and -132.88, Overvalued between 261.68 and 458.96, and Strongly Overvalued above 458.96. The current Forward EV/EBITDA of 23.30 falls within the Historic Trend Line -Fairly Valued range.

22.11

EV/EBIT

Dynavax Technologies Corp. (DVAX) has a current EV/EBIT of 22.11. The 5-year average EV/EBIT is 46.73. The thresholds are as follows: Strongly Undervalued below -131.26, Undervalued between -131.26 and -42.27, Fairly Valued between 135.72 and -42.27, Overvalued between 135.72 and 224.72, and Strongly Overvalued above 224.72. The current Forward EV/EBIT of 22.11 falls within the Historic Trend Line -Fairly Valued range.

3.30

Dynavax Technologies Corp. (DVAX) has a current PS of 3.30. The 5-year average PS is 4.25. The thresholds are as follows: Strongly Undervalued below 0.86, Undervalued between 0.86 and 2.55, Fairly Valued between 5.95 and 2.55, Overvalued between 5.95 and 7.64, and Strongly Overvalued above 7.64. The current Forward PS of 3.30 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Dynavax Technologies Corp. (DVAX) has a current P/OCF of 0.00. The 5-year average P/OCF is 32.66. The thresholds are as follows: Strongly Undervalued below -105.69, Undervalued between -105.69 and -36.51, Fairly Valued between 101.84 and -36.51, Overvalued between 101.84 and 171.02, and Strongly Overvalued above 171.02. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

17.80

P/FCF

Dynavax Technologies Corp. (DVAX) has a current P/FCF of 17.80. The 5-year average P/FCF is 50.76. The thresholds are as follows: Strongly Undervalued below -329.56, Undervalued between -329.56 and -139.40, Fairly Valued between 240.92 and -139.40, Overvalued between 240.92 and 431.08, and Strongly Overvalued above 431.08. The current Forward P/FCF of 17.80 falls within the Historic Trend Line -Fairly Valued range.

Dynavax Technologies Corp (DVAX) has a current Price-to-Book (P/B) ratio of 2.37. Compared to its 3-year average P/B ratio of 2.56 , the current P/B ratio is approximately -7.43% higher. Relative to its 5-year average P/B ratio of 6.19, the current P/B ratio is about -61.66% higher. Dynavax Technologies Corp (DVAX) has a Forward Free Cash Flow (FCF) yield of approximately 6.35%. Compared to its 3-year average FCF yield of 5.06%, the current FCF yield is approximately 25.39% lower. Relative to its 5-year average FCF yield of 5.87% , the current FCF yield is about 8.19% lower.

2.37

P/B

Median3y

2.56

Median5y

6.19

6.35

FCF Yield

Median3y

5.06

Median5y

5.87

Competitors Valuation Multiple

The average P/S ratio for DVAX's competitors is 455.74, providing a benchmark for relative valuation. Dynavax Technologies Corp Corp (DVAX) exhibits a P/S ratio of 3.30, which is -99.28% above the industry average. Given its robust revenue growth of 17.67%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of DVAX decreased by 15.43% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 21.82 to 28.38.

The secondary factor is the Revenue Growth, contributed 17.67%to the performance.

Overall, the performance of DVAX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

17.67%

80.63M → 94.88M

Revenue Growth

30.06%

21.82 → 28.38

Margin Expansion

-63.16%

-81.60 → -30.06

P/E Change

-15.43%

12.77 → 10.80

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Dynavax Technologies Corp (DVAX) currently overvalued or undervalued?

What is Dynavax Technologies Corp (DVAX) fair value?

DVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Dynavax Technologies Corp (DVAX) is between 294.64 to 303.53 according to relative valuation methord.

How does DVAX's valuation metrics compare to the industry average?

What is the current P/B ratio for Dynavax Technologies Corp (DVAX) as of Dec 15 2025?

As of Dec 15 2025, Dynavax Technologies Corp (DVAX) has a P/B ratio of 2.37. This indicates that the market values DVAX at 2.37 times its book value.

What is the current FCF Yield for Dynavax Technologies Corp (DVAX) as of Dec 15 2025?

As of Dec 15 2025, Dynavax Technologies Corp (DVAX) has a FCF Yield of 6.35%. This means that for every dollar of Dynavax Technologies Corp’s market capitalization, the company generates 6.35 cents in free cash flow.

What is the current Forward P/E ratio for Dynavax Technologies Corp (DVAX) as of Dec 15 2025?

As of Dec 15 2025, Dynavax Technologies Corp (DVAX) has a Forward P/E ratio of 18.79. This means the market is willing to pay $18.79 for every dollar of Dynavax Technologies Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Dynavax Technologies Corp (DVAX) as of Dec 15 2025?

As of Dec 15 2025, Dynavax Technologies Corp (DVAX) has a Forward P/S ratio of 3.30. This means the market is valuing DVAX at $3.30 for every dollar of expected revenue over the next 12 months.

DVAX Valuation